Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 5/20 | 0.65 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.65 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspirin Trelamine SCHEMBL30345899 | 1.00 | SCN1A (0.65) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL2578309 | 0.99 | SCN1A (0.64) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL30058370 | 0.99 | SCN1A (0.64) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL28209327 | 0.99 | SCN1A (0.64) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL27964262 | 0.97 | SCN1A (0.66) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Hydrochloric Acid SCHEMBL31465590 | 0.96 | SCN1A (0.61) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL2472615 | 0.95 | SCN1A (0.63) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL29481379 | 0.95 | SCN1A (0.63) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| SCHEMBL12715097 | 0.93 | PTGS2 (0.60) | SCN1ASCN2ASCN3APTGS2KDM4E | |
| Aspirin Trelamine SCHEMBL25267494 | 0.93 | SCN1A (0.60) | SCN1ASCN2ASCN3APTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2849738-B1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOSITION THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO LTD (CN) | 2023-12-06 | — | — | EP | claimed |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | PREMIER RESEARCH INTERNATIONAL, LLC | 2023-11-14 | — | — | US | claimed |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | TECHFIELDS INC. (US) | 2023-05-25 | — | — | US | claimed |
| EP-3279182-B1 | ACETYLSALICYLIC ACID DERIVATIVE CRYSTAL AND PREPARATION METHOD AND USE THEREOF | ZHEJIANG YUEJIA PHARMACEUTICALS CO LTD (CN) | 2021-05-26 | — | — | EP | claimed |
| CN-112521305-A | Novel high-penetration medicine for treating Parkinson's disease and medicine composition thereof | 苏州泰飞尔医药有限公司 | 2021-03-19 | — | — | CN | claimed |
| CN-105439877-B | The prodrug of positively charged water-soluble Diflunisal and related compound | 于崇曦 | 2019-07-23 | — | — | CN | claimed |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | TECHFIELDS PHARMA CO., LTD | 2019-05-16 | — | — | US | claimed |
| US-9718766-B2 | High penetration drugs and their compositions thereof for treatment of parkinson diseases | TECHFIELDS PHARMA CO., LTD. (CN) | 2017-08-01 | — | — | US | claimed |
| EP-2994453-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | Techfields Pharma Co., Ltd. (CN) | 2016-03-16 | — | — | EP | claimed |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | PREMIER RESEARCH INTERNATIONAL, LLC | 2016-01-07 | — | — | US | claimed |
| WO-2014139161-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | TECHFIELDS PHARMA CO., LTD. (CN) | 2014-09-18 | — | — | WO | claimed |
| US-12454506-B2 | Benzoate derivatives | ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12403117-B2 | Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative | ZHEJIANG YUEJIA PHARMACEUTICALS CO., LTD (CN) | 2025-09-02 | — | — | US | disclosed |
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | TECHFIELDS INC. (JP) | 2025-03-27 | — | — | US | disclosed |
| US-20240360073-A1 | BENZOATE DERIVATIVES | ZHEJIANG YUEJIA PHARMACEUTICALS CO LTD (CN) | 2024-10-31 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-24 | — | — | US | disclosed |
| EP-2038251-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | Techfields Biochem Co. Ltd (CN) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008007171-A1 | POSITIVELY CHARGED WATER-SOLUBLE PRODRUGS OF ASPIRIN | TECHFIELDS BIOCHEM CO. LTD (CN) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454506-B2 | Benzoate derivatives | NFKBIA, NFKB2, NFKB1 | SCN1A 3843/4885SCN2A 2983/4885SCN3A 3792/4885 |
| US-11813256-B2 | High penetration prodrug compositions and pharmaceutical compositon thereof for treatment of pulmonary conditions | CPA3, PAH, HCAR2 | SCN1A 3747/4885SCN2A 4027/4885SCN3A 3125/4885 |
| US-20250099491-A1 | PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES WITH HIGH PENETRATION PRODRUGS OF ASPIRIN AND OTHER NSAIDS | PTGS1, PTGIS, PTGS2 | SCN1A 2056/4885SCN2A 2022/4885SCN3A 1484/4885 |
| US-12403117-B2 | Stable pharmaceutical composition containing non-steroidal anti-inflammatory drug derivative | PTGES, PTGES2, IL17A | SCN1A 770/4885SCN2A 906/4885SCN3A 1255/4885 |
| US-20160002157-A1 | NOVEL HIGH PENETRATION DRUGS AND THEIR COMPOSITIONS THEREOF FOR TREATMENT OF PARKINSON DISEASES | ABCB1, PARK7, SLC5A7 | SCN1A 3098/4885SCN2A 2996/4885SCN3A 2630/4885 |
| US-20240360073-A1 | BENZOATE DERIVATIVES | NFKBIA, NFKB2, NFKB1 | SCN1A 3843/4885SCN2A 2983/4885SCN3A 3792/4885 |
| US-20230157952-A1 | METHOD FOR IMPROVING THE STABILITY OF A PHARMACEUTICAL COMPOSITION COMPRISING A HIGH PENETRATION DRUG, AND THE PHARMACEUTICAL COMPOSITION OBTAINED THEREFROM | SLC7A1, ABCG2, SLCO4C1 | SCN1A 3029/4885SCN2A 3388/4885SCN3A 3102/4885 |
| US-20190142818-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS AND PHARMACEUTICAL COMPOISITON THEREOF FOR TREATMENT OF PULMONARY CONDITIONS | CPA3, HCAR2, HRH4 | SCN1A 3330/4885SCN2A 3440/4885SCN3A 2892/4885 |
| US-20090238763-A1 | HIGH PENETRATION COMPOSITIONS AND USES THEREOF | HPGDS, PTGIS, PTGES | SCN1A 846/4885SCN2A 918/4885SCN3A 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.